Driven By The Urgency Of Cancer Patients Who Need Effective Therapies

Our mission is to inspire hope by delivering targeted therapies for those battling cancers.

A Focused Pipeline Portfolio

By leveraging our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, we have developed a pipeline of small molecule kinase inhibitor candidates for difficult-to-treat, genomically-defined cancers.

An Experienced Team of Precision Oncology Leaders

Latest News

Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board

Kinnate Biopharma Closes $98 Million Series C Financing

Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer

Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

Help Us Improve Lives

Have A Question?